KB-1358

IBI334-hIgG1

Home » Antibody » IBI334-hIgG1

Background

EGFR is a tyrosine kinase receptor that plays a vital role in cell proliferation, differentiation, and survival through essential signaling pathways. Abnormal EGFR signaling can cause excessive cell growth and the formation of tumors. Conversely, B7-H3 is an immune checkpoint molecule that primarily inhibits the activation and expansion of T cells, thus preventing an overactive immune response. EGFR/B7-H3 dual antibodies are targeted drugs that specifically target these two molecules. They function by inhibiting EGFR signaling to impede tumor cell proliferation and by blocking B7-H3 signaling to activate T cells, thereby enhancing their ability to attack tumor cells. Consequently, the primary mechanism of action of EGFR/B7-H3 dual antibody therapy is to simultaneously inhibit tumor growth and enhance the immune system's ability to kill, resulting in a dual assault on tumors.

Specifications

Catalog Number:
KB-1358
Cell Line Name:
IBI334-hIgG1
Price:
0
Host Cell Line:
EXPI-CHO
Target:
B7-H3
Species Reactivity:
Human
Application:
ELISA
Purification Method:
Affinity purified
Concentration:
>2mg/mL
Purity:
>95% by SDS-PAGE and SEC-HPLC
Endotoxin Level:
<0.5 EU/mg as determined by the LAL method
Sterility:
0.2¦Ìm filtered
Formulation:
20mM sodium citrate,150mM NaCl, pH5.5
Storage:
Stable for twelve months from date of receipt when stored at -20¡ãC to -80¡ãC; Stored at 2-8¡ãC for one month without detectable loss of activity.
Bio Safety Level:
1
Validation:
SDS-PAGE | SEC-HPLC | ELISA

References

1. Next©generation sequencing of tissue and circulating tumor DNA: Resistance mechanisms to EGFR targeted therapy in a cohort of patients with advanced non©small cell lung cancer. 2. Zhao Q, Liu J, Yang S. Therapeutically targeting B7-H3 via chimeric antigen receptors and bispecific killer cell engagers in non-small cell lung cancer. Journal of Immunology. 2018:200.
Please enable JavaScript in your browser to complete this form.